4L2-P13D is an IL-11 antagonist with an IC50 of 2.8 μM. 4L2-P13D has a K D of 11 nM for hIL-11. 4L2-P13D exhibits antifibrotic and renoprotective activities. 4L2-P13D can be used in the research of renal fibrosis [1].
In Vivo, 4L2-P13D (0.5-2 mg/kg; s.c.; daily administration; 7 days) exhibits potent anti-renal fibrosis activity in the UUO mouse model[1].
In Vitro, 4L2-P13D (0.5-5 μM; 72 h) reduces the expression of profibrotic factors (FN1, COL1A1) in TGF-β1-induced HK-2 cells in a dose-dependent manner[1]. 4L2-P13D (0-50 μM; 24 h) exhibits no cytotoxicity against HK-2 cells even at concentrations as high as 50 μM[1].
References:
[1]. An C, et al. De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy. J Med Chem. 2025;68(19):20377-20388.
In Vivo, 4L2-P13D (0.5-2 mg/kg; s.c.; daily administration; 7 days) exhibits potent anti-renal fibrosis activity in the UUO mouse model[1].
In Vitro, 4L2-P13D (0.5-5 μM; 72 h) reduces the expression of profibrotic factors (FN1, COL1A1) in TGF-β1-induced HK-2 cells in a dose-dependent manner[1]. 4L2-P13D (0-50 μM; 24 h) exhibits no cytotoxicity against HK-2 cells even at concentrations as high as 50 μM[1].
References:
[1]. An C, et al. De Novo Discovery of a Macrocyclic Peptide Antagonist of Interleukin-11 with Antirenal Fibrotic Efficacy. J Med Chem. 2025;68(19):20377-20388.